Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC
Share
Subscribe
Highlights from the PER® CME activity "Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, experts Narjust Florez, MD, FASCO; David Carbone, MD, PhD; and Edward Garon, MD, MS; discuss the use of KRAS-, NRG1-, MET-, and ROS1-targeting agents to transform patient care in advanced non–small cell lung cancer (NSCLC).
Earn CME credit by completing the full accredited activity (available through March 27, 2027):
https://www.gotoper.com/ltb26nsclc-activity
This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AbbVie Inc, Lilly, and Partner Therapeutics.
This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.